Repligen Acquires AtollBy
Repligen Corporation, a life sciences company focused on bioprocessing technology, today has acquired Atoll GmBH of Weingarten, Germany, an innovator and manufacturer of MediaScout pre-packed chromatography columns used in process development and clinical manufacturing of biologic drugs. The acquisition of Atoll expands Repligen's pre-packed column chromatography portfolio into high throughput process development screening, complementing the company's existing strength in clinical production-scale columns.
Repligen purchased Atoll from UV-Cap GmbH & Co. KG on April 1, 2016 for a combination of $9.1 million in cash and 538,700 shares of Repligen common stock, for total upfront consideration of approximately $22.5 million. The agreement also includes a potential payment of EUR 1.0 million ($1.13 million), contingent on achieving a predetermined revenue target for the year 2016.